TCT AP 2015 Seoul, Korea

Valve-in-Valve Implants for Failed Bioprosthetic Heart Valves



Eberhard Grube MD, FACC, FSCAI

University Hospital, Dept of Medicine II, Bonn, Germany Stanford University, Palo Alto, California, USA

Eberhard Grube, MD

Physician Name

Eberhard Grube, MD

Company/Relationship

Medtronic, CoreValve: C, SB, AB, OF Direct Flow: C, SB, AB Mitralign: AB, SB, E Boston Scientific: C, SB, AB Biosensors: E, SB, C, AB Kona: AB, E Abbott Vascular: AB InSeal Medical: AB, E, Valtech: E, SB, Claret: SB Keystone: AB Shockwave: E, AB

Background


- Reoperation (redo) is the standard of care for failed bioprosthetic valves.
- However, for patients who are elderly or have associated comorbidities, redo surgery may not be a viable option.
 - Operative mortality for elective redo AVR ranges from 2% to 7%. It can increase to 30% in high-risk and non-elective patients¹
 - Risk is especially high for patients with previous sternotomy and are frail.
- Transcatheter aortic valve replacement (TAVR) within a failing bioprosthesis (TAV in SAV) provides a minimally invasive alternative to redo surgery.
- While TAV in SAV procedures have been described since 2007, the largest available data set on this procedure from the Global Valve in Valve Registry was first published in 2012 and updated in 2014^{2,3}. Recent prospective clinical trial experience is also now available.

¹Piazza, et al., J Am Coll Cardiol Cardiovasc Interv 2011; 4(7): 721-32, ²Dvir, et al., Circulation 2012; 126: 2335-2344, ³Dvir et al., JAMA 2014; 312(2):162-170.

Considerations about SAV "Mode of Failure"

Stated Minimal Inside Diameter


Does not consider the space taken by the bioprosthetic tissue.





Failure Presentation

Regurgitation from Tear and Wear...



...or Stenosis from Calcification or Pannus





Valve in Valve Procedure Overview

Valve in Valve Procedure Overview

 Identify failed SAV



 Measure SAV and size accordingly



3

Implant




Image from: Fariley SL, Jeganathan R, Manoharan G, et al. Early Experience of Implantation of the New CoreValve Evolut in Degenerated Bioprosthetic Aortic Valves. Catherization and Cardiovascular Interventions 00:00-00 (2013)


Valve in Valve Pre-Procedure

Pre-procedure Steps for Sizing and Orientation are Critical:

- Determine the SAV's mode of failure
- Identify the failed SAV
- Determine (inside) diameter of SAV
 - Use valve-in-valve sizing guides
 - Use CT and other imaging to measure annulus diameter
 - Use manufacturer annulus sizing chart to determine appropriate valve size



Edwards Perimount® 2800 Valve*




Valve in Valve Sizing


Best Practice: Utilize the Imaging techniques consistent with native TAVR implant methodology.

Computed tomography (CT) is required. Instead of measuring the native annulus, measure the:

- Inside diameter of SAV inflow (at the annulus)
- Distance between left and right ostia and the valve



Valve Positioning Location of Angiographic Markers in Surgical Valves Varies



Case Examples


Structural Valve Deterioration Aortic Regurgitation











Minimum intrapped material between the 2 valves positively influence the resulting EOA and PPM +






Structural Valve Deterioration Aortic Stenosis

















Intrapped material between the 2 valves affect significantly the resulting EOA and PPM ++



Lotus valve in Failed Surgical Bioprosthesis (Mosaic)

Direct valve implantation

23mm Lotus

Marker at 4 mm above annulus



Lotus valve in Failed Surgical Bioprosthesis (Mosaic)

Final Result




Hemodynamic peak to peak Gradient : 5-7 mm Hg

Lotus valve in Failed Surgical Bioprosthesis (Freestyle)

Case 2: Stentless valve Dacron Graft + Freestyle 27 (2010)






Lotus valve in Failed Surgical Bioprosthesis (Freestyle)

Direct valve implantation

23mm Lotus

Marker at 2mm above annulus



Lotus valve in Failed Surgical Bioprosthesis (Freestyle)

Final result



Hemodynamic peak to peak Gradient : 0 mm Hg

Clinical Evidence

Valve in Valve Impact of Design

Increased post procedural gradient may be anticipated in smaller bioprostheses due to small EOA for the TAVI device¹.



Supra-annular design maximizes the available orifice area within the bioprosthesis²



Intra-annular design may lead to under-expansion, reducing the potential orifice area²

- 2012 (*Circulation*) Global Valve in Valve registry: 202 patients from 38 sites¹.
- 2013 update (TCT): 554 patients from 55 sites².
- 2014 (JAMA):1-year outcomes 459 patients from 55 sites³.



Original Investigation

Aortic Valve-in-Valve: Insights from the Global Regist

Danny Dvir, MD On behalf of the VIVID Registry investigators



Danny Dvir, MD: John G. Webb, MD; Sabine Bleiziffer, MD; Miralem Pasic, MD, PhD; Ron Waksman, MD; Susheel Kodali, MD; Marco Barbanti, MD; Azeem Latib, MD; Ulrich Schaefer, MD; Josep Rodés-Cabau, MD; Hendrik Treede, MD; Nicolo Piazza, MD, PhD; David Hildick-Smith, MD; Dominique Himbert, MD; Thomas Walther, MD; Christian Hengstenberg, MD; Henrik Nissen, MD, PhD; Raffi Bokeredjian, MD; Patrizia Presbitoro, MD; Enrico Ferrari, MD; Arnit Segev, MD; Arend de Weger, MD; Stephan Windecker, MD; Neil E. Moat, FRCS; Massimo Napodano, MD; Manuel Wilbring, MD; Alfredo G, Cerillo, MD; Stephan Brocker, MD; Didier Tchetche, MD; Thierry Lefevre, MD; Federico De Marco, MD; Claudia Fiorina, MD; Anna Sonia Petronio, MD; Rui C, Teles, MD; Luca Testa, MD; Jean-Claude Laborde, MD; Martin B, Leon, MD; Ran Kornowski, MD; for the Valve-in-Valve International Data Bogistry Investigators



tct 25 October 2013


Most recent publication (now VIVID) show high survival and low rates of major stroke.

Original Invited gatice	
Transcatheter Aortic Valve Implantation	
in Failed Bioprosthetic Surgical Valves	
Temp Der MIC Inter-G Vehlt. MIC Sahner Dachten MIC Headen Faus, MIC Heil Sam Wahnman MIC Sahner Teilen, MIC Seitzer Kanner, Sahn MIC Sahner Sahner, Sahn MIC Sahner Sahner, Sahn MIC Sahner Sahner Sahner MIC Sahner Mich Sahner MIC Sahner MIC Sahner Mich Sahner MIC Sahner Mich MIC Sahner	ed wilded Solder, KED organ, MC, Forenski Pentiteren, MC, aportani, KED, Openan Williamg, DO, andra Torrens, MC
	D Autor Main Marine a
MARKETMACE During the according to the child have of the period based based with degree that mechanical valves. It is expected that writerits with screepingly pleases with degree state	Statuter
Incertaintese in the next have yeers. Transactively action where in volve implementation is a large measure approach for patients with structural value determination, however, a comprehensive evaluation of survivel after the procedure has not yet later performed.	and the
BLOCINE To deprese the survey of patients after transplanter server's very implementary much field surgery to provide to serve.	
INCOMENDATION AND PARTICIPANTS. Commission for purried wave and using a	
multinutural valve in-volve registry that included-GG patients with departmented technologies when a despiring valve in valve multinotics between 2001 and May 1013 m	
Its central linear-age, This [30] (3-6] years, term men median becardy of Thotacc targets motality predictory ecole. Il 214, [Interquantia range, 725-1636]. Sangkal velves serve	
Interface to share is the rest of the rest of the memory of an end of the rest	
NEW STREET, SALENDARD STATUS, and an other tot reat second streets and an other total second street and	
GLIE 21. Motor of bogotesteen failure sees mersons in - thi (34.4%), regargination in - 188	
[30,3m]), and contained in - sim (20,3m). The standard group had a higher parameters of anial values (37% vs 20,0% and 20,0% in the negogigation and continued prices.	
repartiesly P + 2005. Within Intendictioning raise in verse implantation, 25 CRU2 partients field & it Prol Fuer report strake, and 25 Hz and of surviving posterior and good	
Surchard data likes will react managing classific the public gas states were	
 survival table web ED 2% 195% CL 90:01% B4-7%, 62 death events: 228 sometion). Patients m the stances prog. had excine 1-year survival IDE 2%, 281%-CL 9%, 24 deaths, 85 	
surviveral minimpaneter with the negligitation group SH 2%, 56%-12, 86, 7%, 56, 7%, 10	
- sharths, 'X, surviversi and the continued group (\$10%, 60%, C, 'X, 8%, 6%, 10 destine, 62 surveyed (1700, 20%)ark partamits with small silves flat worse (year surveyed (74, 6%, 56%))	
CT. 66.75-81.452 77 Martie, 57 Service) is with international space value (91.81, 985) CT.	
75.9% 48 7% 27 Moths, 57 Sorveroru and with longs values (35.9% 5), 85 7% 56 7% 7 deaths, 73 services (21.9 - 0.0). Factors associated with manufally within 1 year included.	
Interng and Legisla bigmethanis (v.D. hm; Internet and 204, 865, 01.194, 267, P - 000, and busine discouns on segregative, Network 1986, 507, 876, 01, 125-108, P - 0081	Active Affiliations Activity Unitariate excitated in the end of the
CONCLUSION AND RELEVANCE IN THE LINE BY OF DATE TO A DATE WHITE THE DATE OF THE PARTY OF THE PARTY OF DATE OF THE PARTY O	schule. General Informations: The
value in valve implantation for degenerated to provide active valves, even in 1 year actively were 15 2%. Springel was been entrong believed and and improvides an and those with	Valence votor ecerclatura tala Degrány investiganos are fainctin
protomitant surgical valve iteration.	etiliari reduciquement. Las requesting Autor-comprise
	MD: 12 April 1 Implified, Sold Transmit 74, Hardbound, W. VED THE Carried's
and 2014 2010 NO. NO. AN ADDRESS CONTRACTOR	Section and the second section of the section of th
	2010
Cripyfight 201# Jonathan Medical Association. Jot rights reserved	New Section 1997

Table 3. Clinical Outcomes	
Outcomes	All (n = 459)
Thirty-day outcomes	(,
Death, No. (%)	35 (7.6)
Cardiovascular death, No. (%)	30 (6.5)
NYHA functional class, No. (%)	
1/11	313 (92.6)
III/IV	25 (7.4)
Major stroke, No. (%) ^a	8 (1.7)
One-year outcomes	
Death, No. (%)	62 (16.8)
NYHA functional class, No. (%)	
1/11	163 (86.2)
III/IV	26 (13.8)
AV area, mean (SD), cm ²	1.38 (0.42)
AV maximal gradient, mean (SD), mm Hg	30 (14.7)
AV mean gradient, mean (SD), mm Hg	16.9 (9.1)

¹Dvir et al., JAMA 2014; 312(2):162-170.

Survival was greater among patients with baseline regurgitation vs. stenosis¹.




In addition to prosthetic valve failure mode, smaller surgical bioprostheses (<21mm), transapical access, and a higher STS score also contributed to mortality¹.

Figure 2. Results of Multiv	/ariable Ar	nalyses f	or Correlates for 1-Year Morta	lity After Valve-in-Valve Impla	intation
	No. of Events	Total	Hazard Ratio (95% CI)		P Value
Overall mortality					
Surgical valve label size					
≤21 mm	28	133	2.04 (1.14-3.67)		02
>2 <mark>1</mark> mm	34	315			.02
Type of valve failure					
Stenosis	34	181	3.07 (1.33-7.08)		008
Regurgitation	12	139			.008
Transapical access					
Yes	34	171	2.25 (1.26-4.02)	-	000
No	30	288			.006
STS score (per 1% incremen	t) ^a		1.01 (1.00-1.01)		<.001


Primary outcomes were equivalent across devices at one year, but self-expandable valves showed more favorable hemodynamics¹

Outcomes		Det		
	All (n = 459)	Self- Expandable (n = 213)	Balloon- Expandable (n = 246)	P Value
One-year outcomes				
Death, No. (%)	62 (16.8)	25 (15)	37 (18.7)	.44
NYHA functional class, No. (%)				
1/11	163 (86.2)	88 (81.6)	75 (82.4)	.89
III/IV	26 (13.8)	10 (18.4)	16 (17.6)	.89
AV area, mean (SD), cm ²	1.38 (0.42)	1.55 (0.41)	1.29 (0.39)	.006
AV maximal gradient, mean (SD), mm Hg	30 (14.7)	25.3 (11.9)	33.3 (16)	<.001
AV mean gradient, mean (SD), mm Hg	16.9 (9.1)	13.5 (7)	19.4 (9.6)	<.001



PARTNER II: Valve in Valve

At TCT 2014, Rakesh Suri reported on 1 year results from the PARTNER II Nested Valve in Valve Registry




Suri, et. al., presented at TCT 2014

PARTNER II: Valve in Valve One Year Mortality

- All-cause and cardiac mortality at 30 days are slightly higher in valve in valve patients from PARTNER II, compared with previous reports on PARTNER II.
- However, the 30 day and 1 year mortality rates are comparable with data from the Global Valve in Valve Registry.

PARTNER II Valve in Valve Nested Registry: All-Cause and Cardiovascular Mortality



CoreValve US Pivotal Expanded Use Study Valve in Valve Results

Low rates of mortality and stroke at 30 days and 6 months

Safety Outcomes

30 Days 3.5 2.8	6 Months 9.0 4.7
2.8	4.7
0.8	1.7
0.8	1.7
1.4	4.5
0.7	2.8
0.7	1.8
0.0	1.0
	0.8 1.4 0.7 0.7

CoreValve™ System Instructions for Use, 2015 Medtronic, Inc. M333433D001

CoreValve US Pivotal Expanded Use Study Valve in Valve Results

55.3% of patients had a 17-20mm annulus. Hemodynamic outcomes are consistent with the pre-existing surgical bioprostheses

Reported SAV Gradients at 1 Year (Mean \pm SD, mmHg)

Valve	19 mm	21 mm
Mosaic (<i>n</i> = 14, 189)	15.3 ± 5.3	14.5 ± 5
Hancock II (n = 9)	NA	12.9 ± 4.2
Perimount† (<i>n</i> = 9, 16)	15	15
Magna (<i>n</i> = 16, 34)	16.7 ± 4	13.8 ± 5
Mitroflow (<i>n</i> = 34, 143)	13.4 ± 5.0	11.4 ± 4
Biocor & Supra (<i>n</i> = 40)	NA	18.8 ± 6
Epic & Supra (<i>n</i> = 49)	NA	19.1 ± 8

Expanded Use TAV in SAV Echo Findings






Table Data Source: Each of the Surgical Valve US Instructions for Use. *†* IFU only reports velocities, extrapolated from published report of FDA approval experience, Frater E, Salomon N, Rainer G, et al. The Carpentier-Edwards Pericardial Aortic Valve: Intermediate Results. Ann Thorac Surg 1992;53:764.71

Valve in Valve with Other Devices

Positive outcomes have been achieved (100% procedural success and 100% 30-day survival)^{1,2}, but increased mean gradient observed with JenaValve implantation¹ possibly due to incomplete stent expansion.



JenaValve 23mm implanted within a 25 mm Sorin Mitroflow bioprosthesis¹



Portico 23 mm implanted within a 19 mm Sorin Mitroflow bioprosthesis²

¹Conradi, et al. *EuroIntervention* 2014; epub ahead of print; epub ahead of print; ²Jeger, et al. *EuroIntervention* 2014; epub ahead of print.

Conclusions

- Valve-in Valve is a safe and effective treatment for degenerative surgical bioprostheses with low rates of mortality, stroke, and other safety outcomes.
- Hemodynamics after valve-in-valve are improved relative to baseline, with supra-annular valve design showing advantages to intra-annular valves.
- Detailed pre-procedure planning and proper procedural technique is essential to achieve a successful outcome:
 - Identifying and assessing the degenerative bioprosthesis
 - Using CT imaging to assess the inner diameter of the valve and the height and location of the coronary ostia relative to the valve commissure posts
 - Using manufacturer guidelines to select the appropriate transcatheter valve size

Thank you very much for Your Attention!

